Jurgi Camblong Sells 43,129 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• CEO Jurgi Camblong sold 43,129 shares on April 14 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, generating about $213,920 and leaving him with 3,664,440 shares (a 1.16% ownership reduction).
• Camblong executed multiple insider sales in March–April totaling 91,569 shares for roughly $448,912 across the listed transactions.
• SOPH traded at $5.12 (market cap ~$350.7M) after reporting a quarterly EPS miss and negative margins; analysts have a consensus rating of Hold with an average price target of $7.50 and mixed buy/sell views.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 43,129 shares of the business's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total value of $213,919.84. Following the completion of the transaction, the chief executive officer directly owned 3,664,440 shares of the company's stock, valued at approximately $18,175,622.40. The trade was a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Stock Up 1.0%

SOPH stock traded up $0.05 on Thursday, hitting $5.12. 125,040 shares of the company's stock were exchanged, compared to its average volume of 181,146. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $5.70. The firm has a 50 day moving average price of $4.74 and a two-hundred day moving average price of $4.72. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The stock has a market cap of $350.67 million, a P/E ratio of -10.04 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million for the quarter, compared to analysts' expectations of $21.20 million. As a group, equities research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SOPH. Guggenheim boosted their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research boosted their target price on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of "Hold" and an average price target of $7.50.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC acquired a new position in shares of SOPHiA GENETICS in the third quarter valued at about $6,708,000. Archon Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after purchasing an additional 14,342 shares during the period. Finally, Royce & Associates LP acquired a new position in shares of SOPHiA GENETICS in the fourth quarter valued at about $2,009,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.